Dr. Lal PathLabs (LALPATHLAB) Q1 24/25 earnings summary

Executive summary

• Achieved 11.3% year-over-year revenue growth in Q1 FY 2025 to ₹602 crore, with PAT up 29.1% to ₹108 crore and EBITDA up 16.2% to ₹170 crore, driven by patient and sample volume increases and expansion into Tier 3 and 4 towns.

• SwasthFit bundled test portfolio contributed 25% to revenue, supporting growth in both routine and specialized diagnostics.

• Suburban Diagnostics integration is progressing, with a focus on volume expansion and process efficiencies.

• Emphasis on operational excellence, digital infrastructure, and expanding the test portfolio, especially in specialized and bundled testing.

• Continued expansion in Tier 3 and 4 towns, with infrastructure and network scale-up driving sustainable volume growth.

Financial highlights

• Q1 FY 2025 revenue: ₹602 crore, up from ₹541 crore in Q1 FY 2024 (11.3% growth); EBITDA: ₹170 crore (16.2% growth), EBITDA margin at 28.2%; PAT: ₹108 crore, up 29.1% year-over-year, PAT margin at 17.9%.

• EPS (Basic): ₹12.8 vs ₹9.9 last year.

• Other income grew to ₹21 crore from ₹14 crore year-over-year.

• Net cash and equivalents as of June 30, 2024: ₹1,044 crore.

• Interim and final dividends of ₹6 per share each were approved and paid.

Outlook and guidance

• Expecting to beat FY 2024 growth rate in FY 2025, with no price increases planned.

• Continued focus on expanding lab infrastructure, especially in North, East, Western, and Southern India.

• Continued investment in digital infrastructure, AI, and data analytics to enhance patient experience and operational efficiency.

• Long-term sustainable EBITDA margin guided at around 27% due to ongoing investments.

• Focus on sustainable growth through operational excellence, tech-driven innovation, and test portfolio expansion.